Journal of Literature Pharmacy Sciences

Meme Kanserinde MMP-2 ve MMP-9'un Rolü
The Role of MMP-2 and MMP-9 in Breast Cancer
Tuba TAŞKANa, Aymelek GÖNENÇa
aGazi Üniversitesi Eczacılık Fakültesi, Biyokimya ABD, Ankara, TÜRKİYE
J Lit Pharm Sci. 2020;9(2):116-24
doi: 10.5336/pharmsci.2020-73622
Article Language: TR
Full Text
ÖZET
 Matriks metalloproteinaz (MMP)lar kalsiyum ve çinko bağımlı proteolitik enzim ailesidir. Bu ailenin bir üyesi olan MMP-2 ve MMP9 jelatini, tip IV, V, VII ve X kollajeni parçalayan tip IV kollajenazlardır. MMP-2 fibroblastlar, endotel hücreleri ve osteoblastlar; MMP-9 inflamatuar hücreler, tümör hücreleri, keratinositler ve epitel hücreleri tarafından sentezlenmektedir. Jelatinazlar, zimojen olarak salgılanırlar ve prodomainlerin bölünmesi ile aktif formlarına dönüşürler. MMP-2 ve MMP-9, meme kanseri hücrelerinde proliferasyon, migrasyon, invazyon ve metastaza yol açmaktadır. Hem MMP-2'nin hem de MMP9'un, meme kanseri tedavisine yönelik olarak polimorfizmlerini ve ekspresyonlarını/aktivitelerini araştıran çalışmalar bulunmaktadır. Meme kanseri progresyonu ve metastazındaki önemli rolleri nedeni ile bu enzimlerin ortak fonksiyonel polimorfizmlerinin, hasta sağkalımını da içeren fenotipik özellikleriyle meme kanseri gelişimine katkıda bulunduğu bildirilmektedir. Di-2-Etilheksilfitalat, PAX6, hücresel prion proteini, natriüretik peptid reseptörü A, aktif lökosit hücre adezyon molekülü, EZH2, eGFR'nin ligand EGF ile etkileşimi, integrin ve integrin olmayan reseptörlerle etkileşim, TF-FVIIa/tripsin aracılı proteaz ile reseptör 2'nin aktivasyonu ile MMP-2 ve/veya MMP-9'un ekspresyonunun arttığı gösterilmektedir. Meme kanserinde invazyon ve metastaz üzerindeki etkileri nedeni ile potansiyel tedavi hedefi olarak MMP-2 ve MMP-9'u inhibe etmeye yönelik olarak Alisol A, Casticin, Orientin, Luteolin ve [15]pyN5 ve [16]pyN5 üzerinde yapılan çalışmalar bulunmaktadır. Bu derlemede, meme kanserinde MMP-2 ve MMP-9'un rolü, polimorfizmleri, bu enzimlerin ekspresyonunu/aktivitesini artıran etkileşimleri, moleküller ile inhibisyonları incelenecek ve son yıllarda yapılan çalışmalar sunulacaktır.

Anahtar Kelimeler: Matriks metalloproteinaz; jelatinaz; MMP-2; MMP-9; meme kanseri
ABSTRACT
 Matrix metalloproteinases (MMPs) are a family of calcium and zinc-dependent proteolytic enzymes. MMP-2 and MMP-9 are members of this family; type IV collagenases which degrade gelatin, types IV, V, VII and X collagen. MMP-2 is synthesized by fibroblasts, endothelial cells and osteoblasts, MMP-9 is synthesized by inflammatory cells, tumor cells, keratinocytes and epithelial cells. Gelatinases are secreted as inactive zymogens and turn into active forms by dividing prodomains. MMP-2 and MMP-9 cause proliferation, migration, invasion and metastasis in breast cancer cells. There are studies investigating the polymorphisms and expressions/activities of both MMP-2 and MMP-9 for breast cancer treatment. Due to their important role in breast cancer progression and metastasis, common functional polymorphisms of these enzymes have been reported to contribute to breast cancer development with their phenotypic properties, including patient survival. Di-2-Ethylhexylphthalate, PAX6, cellular prion protein, Natriuretic peptide receptor A, active leukocyte cell adhesion molecule, EZH2, interaction of eGFR with ligand EGF, interaction with integrin and non-integrin receptors, with TFFVIIa / trypsin mediated protease of receptor 2 activation is shown to increase expression of MMP-2 and / or MMP-9. There are studies on Alisol A, Casticin, Orientin, Luteolin and [15] pyN5 and [16] pyN5 to inhibit MMP-2 and MMP-9 as potential treatment targets due to their effects on invasion and metastasis in breast cancer. In this review, in breast cancer MMP-2 and MMP-9 role, polymorphisms, interactions that increase the expression / activity of these enzymes, and their inhibition with molecules will be presented and studies conducted in recent years will be presented.

Keywords: Matrix metalloproteinase; gelatinase: MMP-2; MMP-9; breast cancer
REFERENCES:
  1. Scherer S, De Souza TB, De Paoli J, Brenol CV, Xavier RM, Brenol JC, et al. Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis. Rheumatol Int. 2010;30(3):369-73. [Crossref]  [PubMed] 
  2. Djurić T, Stojković L, Zivković M, Končar I, Stanković A, Djordjević A, Alavantić D. Matrix metalloproteinase-1 promoter genotypes and haplotypes are associated with carotid plaque presence. Clin Biochem. 2012;45(16-17):1353-6. [Crossref]  [PubMed] 
  3. Zivković M, Djurić T, Dincić E, Raicević R, Alavantić D, Stanković A. Matrix metalloproteinase-9 −1562 C/T gene polymorphism in Serbian patients with multiple sclerosis. J Neuroimmunol. 2007;189(1-2):147-50. [Crossref]  [PubMed] 
  4. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci. 1999;55(4):639-52. [Crossref]  [PubMed] 
  5. Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem. 1999;274(31):21491-4. [Crossref]  [PubMed] 
  6. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516. [Crossref]  [PubMed]  [PMC] 
  7. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2008;29(5):290-308. [Crossref]  [PubMed]  [PMC] 
  8. Gill SE, Kassim SY, Birkland TP, Parks WC. Mouse models of MMP and TIMP function. Methods Mol Biol. 2010;622:31-52. [Crossref]  [PubMed] 
  9. Itoh Y, Ito N, Nagase H, Evans RD, Bird SA, Seiki M. Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol Biol Cell. 2006;17(12):5390-9. [Crossref]  [PubMed]  [PMC] 
  10. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 1995;375(6528):244-7. [Crossref]  [PubMed] 
  11. Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem. 1996;271(15):9135-40. [Crossref]  [PubMed] 
  12. Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes Dis. 2015;2(1):26-34. [Crossref]  [PubMed]  [PMC] 
  13. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 2012;1825(1):29-36. [Crossref]  [PubMed] 
  14. Agnieszka Jezierska, Tomasz Motyl. Matrix Metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009;15(2):RA32-40. [PubMed] 
  15. Tallant C, Marrero A, Gomis-Rüth FX. Matrix metalloproteinases: fold and function of their catalytic domains. Biochim Biophys Acta. 2010;1803(1):20-8. [Crossref]  [PubMed] 
  16. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15(2):201-12. [Crossref]  [PubMed]  [PMC] 
  17. Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, Murphy G. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J. 1995;309(Pt 1):299-306. [Crossref]  [PubMed]  [PMC] 
  18. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2(4):252-7. [Crossref]  [PubMed]  [PMC] 
  19. Davies KJ. The complex ınteraction of matrix metalloproteinases in the migration of cancer cells through breast tissue stroma. Int J Breast Cancer. 2014;839094. [Crossref]  [PubMed]  [PMC] 
  20. Chakrabarti S, Patel KD. Matrix metalloproteinase-2 (MMP-2) and MMP-9 In pulmonary pathology. Exp Lung Res. 2005;31(6):599-621. [Crossref]  [PubMed] 
  21. Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Dorent R, Perennec J, et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail. 1999;1(4):337-52. [Crossref]  [PubMed] 
  22. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9-34. [Crossref]  [PubMed] 
  23. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem. 2007;101(4):816-29. [Crossref]  [PubMed] 
  24. Feller L, Kramer B, Lemmer J. Pathobiology of cancer metastasis: a short account. Cancer Cell Int. 2012;12:24. [Crossref]  [PubMed]  [PMC] 
  25. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2011;41(2):271-90. [Crossref]  [PubMed]  [PMC] 
  26. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer, J Clin Oncol. 2009;27(31):5287-97. [Crossref]  [PubMed]  [PMC] 
  27. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005;87(3-4):287-97. [Crossref]  [PubMed] 
  28. Yu XF, Han ZC. Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol Histopathol. 2006;21(5):519-31. [PubMed] 
  29. Rydlova M, Holubec Jr L, Ludvikova Jr. M, Kalfert D, Franekova J, Povysil C, et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res. 2008;28(2B):1389-97. [PubMed] 
  30. Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer. 1999;79(11-12):1828-35. [Crossref]  [PubMed]  [PMC] 
  31. Murnane MJ, Cai J, Shuja S, McAneny D, Klepeis V, Willett JB. Active MMP-2 effectively identifies the presence of colorectal cancer. Int J Cancer. 2009;125(12):2893-902. [Crossref]  [PubMed]  [PMC] 
  32. Jiyon L, Park SH, Lee J, Chun H, Choi MK, Yoon JH, et al. Differential effects of luteolin and its glycosides on invasion and spoptosis in MDA-Mb-231 triple-negative breast cancer cells. EXCLI J. 2019;18:750-63. [PubMed] 
  33. Huang H. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances. Sensors (Basel). 2018;18(10):3249. [Crossref]  [PubMed]  [PMC] 
  34. Peng WJ, Yan JW, Wan YN, Wang BX, Tao JH, Yang GJ, et al. Matrix metalloproteinases: a review of their structure and role in systemic sclerosis. Clin Immunol. 2012;32(6):1409-14. [Crossref]  [PubMed] 
  35. Mendes O, Kim HT, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis. 2005;22(3):237-46. [Crossref]  [PubMed] 
  36. Jezierska A, Matysiak W, Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 2006;12(8):63-73. [PubMed] 
  37. Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, Bautista-Lam JR, Andrade-Soto M, Jonguitud-Olguin G, et al. Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest. 2008;65(1):68-72. [Crossref]  [PubMed] 
  38. Fabienne G, Li WQ, Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat. 2004;88(3):197-204. [Crossref]  [PubMed] 
  39. Rahimi Z, Yari K, Rahimi Z. Matrix metalloproteinase-9 -1562T allele and its combination with MMP-2 -735 C allele are risk factors for breast cancer. Asian Pac J Cancer Prev. 2015;16:1175-9. [Crossref]  [PubMed] 
  40. Zhang X, Jin G, Li J, Zhang L. Association between four MMP-9 polymorphisms and breast cancer risk: a meta-analysis. Med Sci Monit. 2015;19(21):1115-23. [Crossref]  [PubMed]  [PMC] 
  41. Merdad A, Karim S, Schulten HJ, Dallo A, Buhmeida A, Al-Thubaity F, et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer ınvasion and metastasis. Anticancer Research. 2014;34(3):1355-66. [PubMed] 
  42. Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006;95(1):65-72. [Crossref]  [PubMed] 
  43. Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem. 2011;44(10-11):869-72. [Crossref]  [PubMed] 
  44. Zhang S, Ma J, Fu Z, Zhang Z, Cao J, Huang L, et al. Promotion of breast cancer cells MDA-MB-231 invasion by di(2-ethylhexyl)phthalate through matrix metalloproteinase-2/-9 overexpression. Environ Sci Pollut Res Int. 2016;23(10):9742-9. [Crossref]  [PubMed] 
  45. Majumder A, Ray S, Banerji A. Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cells. Mol Cell Biochem. 2019;452(1-2):111-21. [Crossref]  [PubMed] 
  46. Dasa K, Prasada R, Ansaria SA, Roya A, Mukherjeeb A, Sen P. Matrix metalloproteinase-2: a key regulator in coagulation proteases mediated human breast cancer progression through autocrine signaling. Biomed Pharmacother. 2018;105:395-406. [Crossref]  [PubMed] 
  47. Urrutia G, Laurito S, Campoy E, Nasif D, Branham MT, Roqué M. PAX6 Promoter Methylation Correlates with MDA-MB-231 Cell Migration, and Expression of MMP-2 and MMP-9. Asian Pac J Cancer Prev. 2018;19(10):2859-2866. [PubMed] 
  48. Gil M, Kim YK, Kim KE, Kim W, Park CS, Lee KJ. Cellular prion protein regulates invasion and migration of breast cancer cells through MMP-9 activity. Biochem Biophys Res Commun. 2016;470(1):213-9. [Crossref]  [PubMed] 
  49. Qu J, Zhao X, Liu X, Sun Y, Wang J, Liu L, et al. Natriuretic peptide receptor a promotes breast cancer development by upregulating MMP-9. Am J Cancer Res. 2019;9(7):1415-28. [PubMed] 
  50. Zaremba-Czogallaa M, Hryniewicz-Jankowskab A, Tabola R, Nienartowicza M, Stachc K, Wierzbickid J, et al. A novel regulatory function of CDKN1A/p21 in TNFα-induced matrix metalloproteinase 9-dependent migration and invasion of triple-negative breast cancer cells. Cell Signal. 2018;47:27-36. [Crossref]  [PubMed] 
  51. Wang G, Zeng Y, Chen S, Li D, Li W, Zhou Y, et al. Localization of TFPI-2 in the nucleus modulates MMP-2 gene expression in breast cancer cells. Sci Rep. 2017;7(1):13575. [Crossref]  [PubMed]  [PMC] 
  52. Jezierska A, Olszewski WP, Pietruszkiewicz J, Olszewski W, Matysiak W, Moty T. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit. 2006;12(7):BR245-56. [PubMed] 
  53. Lai XX, Li G, Lin B, Yang H. Interference of Notch 1 inhibits the proliferation and invasion of breast cancer cells: Involvement of the β-catenin signaling pathway. Mol Med Rep. 2018;17(2):2472-8. [Crossref]  [PubMed] 
  54. Chien YC, Liu LC, Ye HY, Wu JY, Yu YL. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway. Am J Cancer Res. 2018;8(3):422-34. [PubMed] 
  55. Lou C, Xu X, Chen Y, Zhao H. Alisol A suppresses proliferation, migration, and ınvasion in human breast cancer MDA-MB-231 cells. Molecules. 2019;24(20):3651. [Crossref]  [PubMed]  [PMC] 
  56. Fan L, Zhang Y, Zhou Q, Liu Y, Gong B, Lü J, et al. Casticin inhibits breast cancer cell migration and invasion by down-regulation of PI3K/Akt signaling pathway. Biosci Rep. 2018;38(6):BSR20180738. [Crossref]  [PubMed]  [PMC] 
  57. Proença S, Antunes B, Guedes RC, Ramilo-Gomes F, Cabral MF, Costa J et al. Pyridine-containing macrocycles display MMP-2/9 inhibitory activity and distinct effects on migration and invasion of 2D and 3D breast cancer models. Int J Mol Sci. 2019;20(20):5109. [Crossref]  [PubMed]  [PMC] 
  58. Besli N, Yenmis G, Tunçdemir M, Sarac EY, Doğan S, Solakoğlu S, et al. Metformin sup­presses the proliferation and invasion through NF-κB and MMPs in MCF-7 cell line. Turkish Journal of Biochemistry. 2019;45(3):122-32. [Crossref] 
  59. Kim SJ, Pham TH, Bak Y, Ryu HW, Oh SR, Yoon DY. Orientin inhibits invasion by suppressing MMP-9 and IL-8 expression via the PKCα/ ERK/AP-1/STAT3-mediated signaling pathways in TPA-treated MCF7 breast cancer cells. Phytomedicine. 2018;50:35-42. [Crossref]  [PubMed] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com